In the phase 2 EXTEND trial, investigators randomly assigned patients with oligometastatic prostate cancer to ADT or MDT + ADT, with further stratification by intermittent vs continuous ADT that was ...

The regulatory approval of the oral estrogen receptor antagonist is for patients whose cancer has an ESR1 mutation and has ...

ENHERTU Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive ...

SAN FRANCISCO -- An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo ...

DecisionDx-SCC, a gene expression profile test, predicted individual risk for metastasis after a squamous cell carcinoma ...

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority ...

Metastatic cancer, the form of cancer that spreads from its original site to distant parts of the body, often provides warning signs long before diagnosis. These signals, frequently dismissed as ...

“Our findings suggest that cancer survivors may be at increased risk of metastatic relapse after common respiratory viral ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan ...

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.